US 11,988,679 B2
Cardiovascular risk evaluations using a risk parameter that includes an HDL and inflammatory biomarker interaction parameter
James D. Otvos, Apex, NC (US); and Irina Y. Shalaurova, Cary, NC (US)
Assigned to LipoScience, Inc., Morrisville, NC (US)
Filed by LipoScience, Inc., Morrisville, NC (US)
Filed on Jan. 4, 2022, as Appl. No. 17/568,392.
Application 17/568,392 is a continuation of application No. 15/915,905, filed on Mar. 8, 2018, granted, now 11,231,429.
Application 15/915,905 is a continuation of application No. 14/852,192, filed on Sep. 11, 2015, granted, now 9,952,232, issued on Apr. 24, 2018.
Claims priority of provisional application 62/049,141, filed on Sep. 11, 2014.
Prior Publication US 2022/0137076 A1, May 5, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 33/48 (2006.01); A61B 5/00 (2006.01); G01N 33/50 (2006.01); G01N 33/92 (2006.01); G01R 33/465 (2006.01); G16H 50/30 (2018.01)
CPC G01N 33/92 (2013.01) [A61B 5/7275 (2013.01); G01R 33/465 (2013.01); G01N 2570/00 (2013.01); G01N 2800/32 (2013.01); G16H 50/30 (2018.01)] 30 Claims
OG exemplary drawing
 
1. A method of determining a risk parameter for cardiovascular disease (CVD) or events, comprising:
providing a Nuclear Magnetic Resonance (NMR) spectrum of an in vitro biosample comprising blood, plasma, or serum from a subject;
obtaining measurements of HDL particles and inflammatory biomarker GlycA in the biosample;
determining NMR-derived concentrations for an HDL particle size subclass and GlycA, based on the measurements;
programmatically calculating a risk parameter value ((HxI)CVD) of the subject using the NMR-derived concentrations for the HDL particle size subclass and GlycA; and
determining the subject's risk of having and/or developing CVD based, at least in part, on the (HxI)CVD risk parameter value.